Obesity News

Semaglutide 2.4 mg was linked to early, sustained improvement in exercise function among patients with obesity-related HF and improved most among those with the largest proportionate weight loss, a speaker reported.

In this video, David Nathan, MD, discusses the effects of COVID-19 on patients with type 2 diabetes.

In this video, David Nathan, MD, discusses the need to bring awareness to the risk factors that lead to the diagnosis of type 2 diabetes.

In this video, David Nathan, MD, discusses the action needed by primary care physicians to help inform and treat patients at risk for type 2 diabetes.

In this video, David Nathan, MD, discusses the side effects of weight loss caused by type 2 diabetes medications and the risks of prescribing these medications to patients without diabetes.

Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty, a speaker reported.

Hepatic steatosis was prevalent among 52% of adults with or without type 2 diabetes and no known history of metabolic dysfunction-associated steatotic liver disease, according to findings published in Obesity.

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.

Use of glucagon-like peptide-1 receptor agonists was associated with an increased risk for gastric food retention during single endoscopic procedures, although this risk was low when combined with colonoscopy, according to research.